MYRELEZ

This brand name is authorized in Estonia, Finland, Ireland, Lithuania, Poland

Active ingredients

The drug MYRELEZ contains one active pharmaceutical ingredient (API):

1 Lanreotide UNII IEU56G3J9C - LANREOTIDE ACETATE

Lanreotide is an octapeptide analogue of natural somatostatin. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. Read about Lanreotide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MYRELEZ Solution for injection	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H01CB03	Lanreotide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1791154, 1791165, 1791176, 1833768, 1833779, 1833780
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 392697, 449026, 549549
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092652, 1092653, 1092654, 1092655, 1092656, 1092657
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100418950, 100418966, 100418972